Impel Pharmaceuticals Inc (IMPLQ)

Market Cap	356.24K
Revenue (ttm)	20.99M
Net Income (ttm)	-74.28M
Shares Out	23.75M
EPS (ttm)	-3.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,335
Open	0.0168
Previous Close	0.0100
Day's Range	0.0150 - 0.0168
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About IMPLQ

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 23, 2021
• Employees: 160
• Stock Exchange: OTCMKTS
• Ticker Symbol: IMPLQ

Financial Performance

In 2022, IMPLQ's revenue was $12.65 million, an increase of 1794.01% compared to the previous year's $668,000. Losses were -$106.31 million, 38.7% more than in 2021.